About Us-北京立康生命科技有限公司

Company Profile

Likang Life Sciences is an innovative enterprise dedicated to development of immune cell therapy, with tumor-specific neoantigen as the target. It aims to provide personalized diagnosis and treatment services for cancer patients with the most cutting-edge precise detection and treatment methods. By now, the company has established close cooperative relationship with Chinese PLA General Hospital (301 Hospital), Beijing Cancer Hospital, and Cancer Hospital Chinese Academy of Medical Sciences, and is preparing several clinical trials. The company's goal is to establish a top cancer treatment center with advanced concepts, leading technologies and standardized services, and lead cancer treatment into a new era of personalized tumor immunotherapy.

Leadership Team

Chen Li, Ph.D.

Founder, Chairman and CEO

Dr. Chen graduated from Beijing Institute of Technology, and then graduated from the Institute of Biophysics of the Chinese Academy of Sciences with a Ph.D.’s degree. He had been working as a postdoctoral researcher in clinical medicine at the Peking University Cancer Hospital & Institute.

Shannon Cheung, M.H.,J.P.,CFA

Co-Founder and Vice Chairman

Mr. Cheung is a serial angel investor and venture builder with over 20 years' experience in investment and corporate finance. He has invested in 40 start-ups in the technology, biotech, medical equipment and services, internet, fintech and media industries. He works closely with entrepreneurs and provides strategic advice, international experience, finance and fundraising expertise to help corporates to grow and become a leader in their respective industries. Mr. Cheung is co-founder/founding partner of Likang, Hero Games, VSPO, DIB and All Football. His other noticeable investments include Alibaba, CMC/Tencent Music Entertainment, Huayiwang Technology Inc, and Ele.me.Mr. Cheung was appointed as Justice of the Peace in 2019 and awarded the Medal of Honour in 2014 for his public and community service by the Government of Hong Kong.

Jia Mingming, M.D.

Chief Scientific Officer

Dr. Jia graduated from Shandong University with a bachelor's degree in medicine. Then, he graduated from the Chinese Center for Disease Control and Prevention with a major in immunology and a doctorate. He had been working as a postdoctoral researcher at the Institute of Biophysics of the Chinese Academy of Sciences. Dr. Jia has been engaged in research on T cell immunity and tumor immunotherapy for a long time, and published many SCI papers and participated in the compilation of several scientific monographs.